SynthesisCNS drugs2019
Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
Synthesis in CNS drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence.Neuropsychopharmacology reports · 2026Review
- Managing Bipolar Disorder With Aripiprazole Once Monthly: From Symptom Stabilization to Functional Recovery.Psychiatry investigation · 2026Article
- Efficacy and Safety of Adjunctive Aripiprazole LAI or Paliperidone LAI for the Management of Patients Suffering from Bipolar I Disorder with Comorbid Obsessive-Compulsive Disorder.Journal of clinical medicine · 2025Article
- The Real-world Effect of Long-acting Injectable Antipsychotics on Annual Medical Costs of Korean Schizophrenia Patients.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study.European archives of psychiatry and clinical neuroscience · 2023Article
- Does the Ranking Matter? A Retrospective Cohort Study Investigating the Impact of theCanadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Article
- Mood Stabilizers of First and Second Generation.Brain sciences · 2023Review
- Application of Antipsychotic Drugs in Mood Disorders.Brain sciences · 2023Review
- High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.Biomedicines · 2023Article
- Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies.Therapeutic advances in psychopharmacology · 2023Review
- Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study.BMC psychiatry · 2022Article
- Existing and emerging pharmacological approaches to the treatment of mania: A critical overview.Translational psychiatry · 2022Review
- Article
- Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.BioMed research international · 2021Article
- Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry.Therapeutic advances in psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-adherence to medications is a major determinant of poor outcome in bipolar disorder. Second-generation long-acting injectable (LAI) antipsychotics help ensure medication adherence which in turn can lead to more favourable outcomes. However, the role of these medications in bipolar disorder is not well established.
objectiveWe sought to review available evidence relating to the efficacy and safety of using second-generation LAI antipsychotics in bipolar disorder.
methodsPRISMA guidelines were followed to systematically review all clinical studies that reported on the efficacy and safety of second-generation LAI antipsychotics in patients with bipolar disorder. We searched Ovid Medline, PsycINFO, and Cochrane Central Register of Controlled Trials from inception to November 2018.
resultsOf 459 identified citations, 53 studies were fully evaluated and 37 met our inclusion criteria. Overall, second-generation LAI antipsychotics were found to be well tolerated and effective for treatment of manic symptoms and preventing mood recurrences in adults with bipolar disorder. However, we found disparity in the evidence available for individual agents. While several randomized controlled trials (RCTs) reported on the use of risperidone LAI in bipolar disorder, we found only one RCT on the use of aripiprazole LAI, and none for use of paliperidone palmitate or olanzapine pamoate (evidence for the former is limited to one observational study and one case series, and for the latter to a single case report). Studies in children and adolescents were restricted to case reports and small open-label studies.
conclusionSecond-generation LAI antipsychotics, particularly risperidone and aripiprazole LAI, may be a safe and effective alternative to oral medications in the management of bipolar disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.